glp-faq
All FAQs
FAQgeneral

Why does retatrutide use glucagon?

Glucagon raises blood sugar — so why add it to a weight-loss drug? In retatrutide, glucagon agonism drives energy expenditure, not glucose release.

Updated May 21, 2026 · 3 min read

Glucagon is usually the villain in blood sugar management — it's what drives glucose production from the liver when you're fasting, which is why type 2 diabetes treatments often aim to suppress glucagon. So why does retatrutide, a drug targeting obesity and metabolic disease, deliberately activate glucagon receptors?

The answer is that glucagon does more than raise blood sugar. In the context of a triple agonist drug that already powerfully controls glucose through GLP-1 and GIP pathways, glucagon receptor activation provides a specific bonus: it increases energy expenditure and promotes fat breakdown. That's the counterintuitive choice that separates retatrutide from tirzepatide.

What glucagon actually does to your metabolism

Glucagon has two main metabolic effects that are relevant here:

  1. Hepatic glucose production — it signals the liver to release stored glucose (glycogenolysis) and make new glucose (gluconeogenesis). This is the problematic effect in diabetes.
  2. Lipolysis and thermogenesis — it activates fat breakdown in adipose tissue and increases energy expenditure in brown adipose tissue. This is the useful effect for weight loss.

In isolation, activating glucagon receptors would raise blood sugar — not ideal. But retatrutide doesn't activate glucagon receptors in isolation. The simultaneous GLP-1 and GIP receptor activation powerfully stimulates insulin secretion, which counteracts the glucagon-driven glucose release. The result is that the hyperglycemic effect of glucagon is effectively neutralized, while the fat-mobilizing and thermogenic effects remain.

The phase 2 trial data supports this: retatrutide didn't cause hyperglycemia in participants without diabetes, and it actually improved glucose metrics in participants who had it.

The energy expenditure angle

The thermogenic effect of glucagon receptor activation is what makes retatrutide theoretically superior to a dual GLP-1/GIP agonist like tirzepatide for weight loss.

Most GLP-1-class drugs work primarily on the intake side — they reduce appetite and slow gastric emptying, so you eat less. That's a powerful mechanism. But they have limited direct effect on how many calories you burn at rest.

Glucagon receptor activation adds an expenditure side effect: it increases the activity of brown adipose tissue (a heat-generating fat depot that burns calories to produce warmth), and it pushes fat cells to release stored triglycerides for oxidation.

Think of it as two levers instead of one: retatrutide pulls appetite down and pushes calorie burning up.

Why this made sense as a drug design choice

Drug developers had to thread a needle here. Too much glucagon activation → unacceptable blood sugar increases. Too little → minimal thermogenic benefit. Eli Lilly's approach with retatrutide was to find a dose ratio where the glucagon signal is substantial enough to produce measurable thermogenesis but balanced by the GLP-1/GIP-driven insulin response.

Whether they threaded it perfectly won't be fully known until phase 3 data matures. The phase 2 trial — 338 participants over 48 weeks — showed the concept works at a mechanistic level. Phase 3 trials with larger, more diverse populations will test whether the balance holds up at scale and across a wider range of metabolic starting points.

What this means for side effects

The glucagon component adds some effects not seen with semaglutide or tirzepatide:

  • Heart rate increase — glucagon is mildly chronotropic (raises heart rate). In the phase 2 trial, retatrutide increased mean heart rate by about 5–6 bpm in the higher-dose groups, more than the 1–2 bpm typically seen with semaglutide
  • Theoretical lean mass effects — glucagon promotes protein catabolism in muscle tissue; whether this translates to more muscle loss than other GLP-1 drugs will be measured in phase 3 body composition substudies
  • Appetite suppression — the GLP-1 component drives this; glucagon may contribute modestly through its own central appetite effects

The heart rate increase in particular is something prescribers will monitor. For most people without pre-existing cardiac conditions, a modest heart rate increase isn't dangerous, but it's a side effect worth knowing about.